These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 16373399)

  • 1. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha.
    Li Y; Kovach A; Suino-Powell K; Martynowski D; Xu HE
    J Biol Chem; 2008 Jul; 283(27):19132-9. PubMed ID: 18469005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation.
    Hondares E; Mora O; Yubero P; Rodriguez de la Concepción M; Iglesias R; Giralt M; Villarroya F
    Endocrinology; 2006 Jun; 147(6):2829-38. PubMed ID: 16513826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
    Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
    Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells.
    Lee HJ; Su Y; Yin PH; Lee HC; Chi CW
    Anticancer Res; 2009 Dec; 29(12):5057-63. PubMed ID: 20044617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INT131: a selective modulator of PPAR gamma.
    Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
    J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
    Shiraki T; Kodama TS; Jingami H; Kamiya N
    Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
    Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
    Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Glucose Sensor ChREBP Links De Novo Lipogenesis to PPARγ Activity and Adipocyte Differentiation.
    Witte N; Muenzner M; Rietscher J; Knauer M; Heidenreich S; Nuotio-Antar AM; Graef FA; Fedders R; Tolkachov A; Goehring I; Schupp M
    Endocrinology; 2015 Nov; 156(11):4008-19. PubMed ID: 26181104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model.
    Palomer X; Alvarez-Guardia D; Rodríguez-Calvo R; Coll T; Laguna JC; Davidson MM; Chan TO; Feldman AM; Vázquez-Carrera M
    Cardiovasc Res; 2009 Mar; 81(4):703-12. PubMed ID: 19038972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
    Berger J; Leibowitz MD; Doebber TW; Elbrecht A; Zhang B; Zhou G; Biswas C; Cullinan CA; Hayes NS; Li Y; Tanen M; Ventre J; Wu MS; Berger GD; Mosley R; Marquis R; Santini C; Sahoo SP; Tolman RL; Smith RG; Moller DE
    J Biol Chem; 1999 Mar; 274(10):6718-25. PubMed ID: 10037770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease.
    Li J; Dai A; Hu R; Zhu L; Tan S
    Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):603-14. PubMed ID: 20732852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.